<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765076</url>
  </required_header>
  <id_info>
    <org_study_id>112147</org_study_id>
    <nct_id>NCT00765076</nct_id>
  </id_info>
  <brief_title>Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older</brief_title>
  <official_title>Observer-blind Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine
      GSK2186877A in people aged 65 years or older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The amendment to the protocol posting: minor change in one inclusion criterion and in one
      secondary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers</measure>
    <time_frame>Day 21</time_frame>
    <description>The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers</measure>
    <time_frame>At Day 0, 21, 42 and 180</time_frame>
    <description>The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker</measure>
    <time_frame>At Day 0, 21, 42 and 180</time_frame>
    <description>The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemagglutinin Inhibition (HI) Antibody Titers</measure>
    <time_frame>At Day 0, 21, 42 and 180</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs) calculated after invitro stimulation with separate vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains.</measure>
    <time_frame>At Day 0, 21, 42 and 180</time_frame>
    <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies</measure>
    <time_frame>At Day 21, 42 and 180</time_frame>
    <description>Seroconversion was defined as the number of vaccinees who had either a prevaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors</measure>
    <time_frame>At Day 21, 42 and 180</time_frame>
    <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies</measure>
    <time_frame>At Day 0, 21, 42 and 180</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>Day 0 -6</time_frame>
    <description>Grade 3 ecchymosis, redness and swelling was &gt;100mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local AEs</measure>
    <time_frame>Day 0 -6</time_frame>
    <description>Duration was defined as the number of days with any grade of local symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>Day 0 -6</time_frame>
    <description>Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was defined as oral temperature ≥ 39.0°C. For other symptoms grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited General AEs</measure>
    <time_frame>Day 0 -6</time_frame>
    <description>Duration was defined as number of days with any grade of general symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>Day 0-20</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom, regardless of intensity or relation to vaccination, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs)</measure>
    <time_frame>Day 0-179</time_frame>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination, grade 3 was defined as symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any AEs of Specific Interest (AESI)</measure>
    <time_frame>Day 0-364</time_frame>
    <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 0-364</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination and related was event assessed by investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix young Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' influenza vaccine GSK2186877A</intervention_name>
    <description>One intramuscular injection at Day 0</description>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Fluarix</intervention_name>
    <description>One intramuscular injection at Day 0</description>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_label>Fluarix young Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy the following criteria at study entry:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study. Specific attention
             should be given to the compliance potential of subjects with suspected or known drug
             or alcohol abuse.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by medical history
             and clinical examination before entering into the study.

        Elderly adults:

        • A man or woman 65 year of age or older at the time of the first vaccination.

        Young adults:

          -  Man or woman between the ages of 18 and 40 years, inclusive.

          -  If the subject is female, she must be of non-childbearing potential or be
             post-menopausal, or if she is of childbearing potential, she must practice adequate
             contraception for 30 days prior to vaccination, have a negative pregnancy test and
             continue such precautions for 2 months after vaccination.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days prior to vaccination, or planned use during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of a vaccine not foreseen by the study protocol up to Visit 4 after vaccination and of
             an influenza vaccine other than the study vaccines up to Visit 4.

          -  Vaccination against influenza since February 2008 with a seasonal influenza vaccine.

          -  Previous vaccination in the last three years with an investigational adjuvanted
             vaccine candidate seasonal or pandemic influenza vaccine.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of hypersensivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s) including egg or chicken protein.

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by clinical evaluation or pre-existing
             laboratory screening tests.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first administration of the study vaccine or planned administration
             during the study.

          -  Any medical conditions in which intramuscular injections are contraindicated.

          -  Pregnant or lactating female.

          -  Female of childbearing age planning to become pregnant or planning to discontinue
             contraceptive precautions.

          -  Any medical condition that in the opinion of the investigator precludes the collection
             of blood volumes as required by the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>March 8, 2012</results_first_submitted>
  <results_first_submitted_qc>March 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2012</results_first_posted>
  <disposition_first_submitted>July 2, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2010</disposition_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Elderly</keyword>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112147</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112147</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112147</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112147</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112147</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112147</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
        </group>
        <group group_id="P3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
        </group>
        <group group_id="B3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.5" spread="5.44"/>
                    <measurement group_id="B2" value="71.5" spread="5.32"/>
                    <measurement group_id="B3" value="26.0" spread="4.91"/>
                    <measurement group_id="B4" value="59.7" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers</title>
        <description>The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)</description>
        <time_frame>Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available. Analysis was only performed for New generation influenza vaccine GSK2186877A Group and Fluarix elderly Group.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers</title>
          <description>The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)</description>
          <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available. Analysis was only performed for New generation influenza vaccine GSK2186877A Group and Fluarix elderly Group.</population>
          <units>cells per million CD4+ Tcells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3371.11" spread="3602.15"/>
                    <measurement group_id="O2" value="2108.10" spread="1728.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers</title>
        <description>The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.</description>
        <time_frame>At Day 0, 21, 42 and 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers</title>
          <description>The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.</population>
          <units>cells per million CD4+ Tcells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pooled vaccine strain Day 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1269.34" spread="1032.60"/>
                    <measurement group_id="O2" value="1309.30" spread="2098.97"/>
                    <measurement group_id="O3" value="2026.14" spread="1004.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled vaccine strain Day 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3371.11" spread="3602.15"/>
                    <measurement group_id="O2" value="2108.10" spread="1728.38"/>
                    <measurement group_id="O3" value="3228.91" spread="1714.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled vaccine strain Day 42 (N=61; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2657.07" spread="1903.38"/>
                    <measurement group_id="O2" value="1540.08" spread="1138.94"/>
                    <measurement group_id="O3" value="2669.41" spread="1391.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled vaccine strain Day 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2105.66" spread="1232.80"/>
                    <measurement group_id="O2" value="1484.11" spread="1024.53"/>
                    <measurement group_id="O3" value="2746.76" spread="1232.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain Day 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.28" spread="421.64"/>
                    <measurement group_id="O2" value="340.57" spread="352.55"/>
                    <measurement group_id="O3" value="793.58" spread="452.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain Day 21 (N=62; 61; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1062.79" spread="1049.87"/>
                    <measurement group_id="O2" value="462.34" spread="712.32"/>
                    <measurement group_id="O3" value="982.18" spread="727.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain Day 42 (N=60; 64; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="822.07" spread="667.91"/>
                    <measurement group_id="O2" value="392.04" spread="498.81"/>
                    <measurement group_id="O3" value="874.34" spread="544.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain Day 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="669.67" spread="579.75"/>
                    <measurement group_id="O2" value="463.94" spread="458.04"/>
                    <measurement group_id="O3" value="973.29" spread="555.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain Day 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.58" spread="340.83"/>
                    <measurement group_id="O2" value="274.47" spread="282.29"/>
                    <measurement group_id="O3" value="437.07" spread="410.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain Day 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="930.98" spread="1262.81"/>
                    <measurement group_id="O2" value="497.49" spread="479.98"/>
                    <measurement group_id="O3" value="667.38" spread="465.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain Day 42 (N=59; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678.88" spread="669.99"/>
                    <measurement group_id="O2" value="331.62" spread="365.40"/>
                    <measurement group_id="O3" value="473.17" spread="500.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain Day 180 (N=59; 62; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640.97" spread="567.70"/>
                    <measurement group_id="O2" value="331.02" spread="324.69"/>
                    <measurement group_id="O3" value="654.30" spread="503.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain Day 0 (N=61; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="672.58" spread="615.67"/>
                    <measurement group_id="O2" value="504.36" spread="588.82"/>
                    <measurement group_id="O3" value="1183.48" spread="582.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain Day 21 (N=62; 60; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1755.55" spread="1961.87"/>
                    <measurement group_id="O2" value="1149.98" spread="1032.36"/>
                    <measurement group_id="O3" value="1861.66" spread="884.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain Day 42 (N=58; 62; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1325.35" spread="1094.01"/>
                    <measurement group_id="O2" value="807.46" spread="639.01"/>
                    <measurement group_id="O3" value="1572.47" spread="719.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain Day 180 (N=57; 60; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1034.78" spread="725.84"/>
                    <measurement group_id="O2" value="778.13" spread="630.32"/>
                    <measurement group_id="O3" value="1640.71" spread="897.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker</title>
        <description>The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.</description>
        <time_frame>At Day 0, 21, 42 and 180</time_frame>
        <population>The analysis was based on According-to-Protocol (ATP) Immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker</title>
          <description>The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.</description>
          <population>The analysis was based on According-to-Protocol (ATP) Immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
          <units>cells per million CD4+ Tcells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pooled strain[CD4-CD40L] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1104.24" spread="987.15"/>
                    <measurement group_id="O2" value="1211.72" spread="1086.88"/>
                    <measurement group_id="O3" value="1879.85" spread="963.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-CD40L] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2817.50" spread="3166.07"/>
                    <measurement group_id="O2" value="1935.66" spread="1597.56"/>
                    <measurement group_id="O3" value="2929.86" spread="1644.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-CD40L] D 42 (N=61; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2447.37" spread="1766.85"/>
                    <measurement group_id="O2" value="1425.02" spread="1082.35"/>
                    <measurement group_id="O3" value="2436.43" spread="1365.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-CD40L] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2036.70" spread="1170.14"/>
                    <measurement group_id="O2" value="1416.78" spread="973.63"/>
                    <measurement group_id="O3" value="2619.74" spread="1167.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4- IFN-γ] D 0 (N=62; 61;44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="832.47" spread="798.10"/>
                    <measurement group_id="O2" value="835.22" spread="1598.81"/>
                    <measurement group_id="O3" value="1403.57" spread="777.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4- IFN-γ] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2305.58" spread="2712.79"/>
                    <measurement group_id="O2" value="1341.17" spread="1195.01"/>
                    <measurement group_id="O3" value="2258.27" spread="1307.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4- IFN-γ] D 42 (N=61; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1775.61" spread="1464.84"/>
                    <measurement group_id="O2" value="997.25" spread="818.08"/>
                    <measurement group_id="O3" value="1849.44" spread="1124.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4- IFN-γ] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1495.36" spread="1031.14"/>
                    <measurement group_id="O2" value="1019.64" spread="790.42"/>
                    <measurement group_id="O3" value="2102.93" spread="1074.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-IL-2] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1085.32" spread="930.22"/>
                    <measurement group_id="O2" value="1119.34" spread="1002.46"/>
                    <measurement group_id="O3" value="1717.41" spread="852.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-IL-2] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2534.86" spread="3188.65"/>
                    <measurement group_id="O2" value="1779.41" spread="1595.66"/>
                    <measurement group_id="O3" value="2690.36" spread="1583.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-IL-2] D42 (N=61; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2205.91" spread="1754.74"/>
                    <measurement group_id="O2" value="1310.05" spread="1062.08"/>
                    <measurement group_id="O3" value="2199.18" spread="1251.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-IL-2] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1837.60" spread="1093.26"/>
                    <measurement group_id="O2" value="1285.14" spread="955.76"/>
                    <measurement group_id="O3" value="2302.51" spread="1042.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-TNF-α] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="874.43" spread="812.98"/>
                    <measurement group_id="O2" value="928.86" spread="1924.68"/>
                    <measurement group_id="O3" value="1425.50" spread="768.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-TNF-α] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2114.47" spread="2448.22"/>
                    <measurement group_id="O2" value="1284.20" spread="1080.26"/>
                    <measurement group_id="O3" value="1999.07" spread="1010.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-TNF-α] D 42 (N=61; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1741.65" spread="1350.73"/>
                    <measurement group_id="O2" value="1012.42" spread="805.86"/>
                    <measurement group_id="O3" value="1752.99" spread="933.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pooled strain[CD4-TNF-α] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1413.29" spread="865.27"/>
                    <measurement group_id="O2" value="1015.29" spread="830.38"/>
                    <measurement group_id="O3" value="1821.04" spread="880.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-CD40L] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387.76" spread="400.63"/>
                    <measurement group_id="O2" value="320.29" spread="338.91"/>
                    <measurement group_id="O3" value="750.57" spread="435.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-CD40L] D 21 (N=62; 61; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="980.10" spread="937.63"/>
                    <measurement group_id="O2" value="462.64" spread="676.17"/>
                    <measurement group_id="O3" value="919.30" spread="679.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-CD40L] D 42 (N=60; 64; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771.49" spread="616.20"/>
                    <measurement group_id="O2" value="365.94" spread="474.72"/>
                    <measurement group_id="O3" value="818.54" spread="522.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-CD40L] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653.13" spread="547.36"/>
                    <measurement group_id="O2" value="466.55" spread="429.28"/>
                    <measurement group_id="O3" value="922.06" spread="511.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-CD40L] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.73" spread="316.94"/>
                    <measurement group_id="O2" value="227.76" spread="266.35"/>
                    <measurement group_id="O3" value="384.02" spread="397.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-CD40L] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="805.56" spread="1066.84"/>
                    <measurement group_id="O2" value="451.52" spread="459.24"/>
                    <measurement group_id="O3" value="602.51" spread="431.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-CD40L] D 42 (N=59; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="592.88" spread="579.07"/>
                    <measurement group_id="O2" value="286.06" spread="333.05"/>
                    <measurement group_id="O3" value="417.15" spread="468.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-CD40L] D 180 (N=59; 62; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609.34" spread="524.50"/>
                    <measurement group_id="O2" value="298.70" spread="295.58"/>
                    <measurement group_id="O3" value="584.68" spread="446.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-CD40L] D 0 (N=61; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647.94" spread="581.98"/>
                    <measurement group_id="O2" value="515.89" spread="566.11"/>
                    <measurement group_id="O3" value="1129.44" spread="573.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-CD40L] D 21 (N=62; 60; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1607.98" spread="1806.43"/>
                    <measurement group_id="O2" value="1077.12" spread="990.77"/>
                    <measurement group_id="O3" value="1737.45" spread="842.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-CD40L] D 42 (N=58; 62; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1246.10" spread="1033.85"/>
                    <measurement group_id="O2" value="763.04" spread="606.04"/>
                    <measurement group_id="O3" value="1472.48" spread="725.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-CD40L] D 180 (N=57; 60; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1011.39" spread="682.07"/>
                    <measurement group_id="O2" value="757.17" spread="611.01"/>
                    <measurement group_id="O3" value="1570.98" spread="843.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4- IFN-γ] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279.24" spread="337.13"/>
                    <measurement group_id="O2" value="258.94" spread="258.55"/>
                    <measurement group_id="O3" value="563.26" spread="323.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4- IFN-γ] D 21 (N=62; 61; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="725.55" spread="752.84"/>
                    <measurement group_id="O2" value="344.39" spread="447.19"/>
                    <measurement group_id="O3" value="680.40" spread="543.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4- IFN-γ] D 42 (N=60; 64; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572.87" spread="520.31"/>
                    <measurement group_id="O2" value="326.66" spread="322.73"/>
                    <measurement group_id="O3" value="623.21" spread="409.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4- IFN-γ] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.26" spread="474.54"/>
                    <measurement group_id="O2" value="363.03" spread="361.43"/>
                    <measurement group_id="O3" value="773.40" spread="486.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4- IFN-γ] D 0 (N=62; 61;44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.92" spread="245.84"/>
                    <measurement group_id="O2" value="164.78" spread="199.00"/>
                    <measurement group_id="O3" value="283.81" spread="267.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4- IFN-γ] D 21 (N=62; 61;43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641.94" spread="944.37"/>
                    <measurement group_id="O2" value="314.63" spread="311.72"/>
                    <measurement group_id="O3" value="403.00" spread="355.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4- IFN-γ] D 42 (N=59; 64;44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.72" spread="501.32"/>
                    <measurement group_id="O2" value="246.18" spread="227.80"/>
                    <measurement group_id="O3" value="331.47" spread="356.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4- IFN-γ] D 180 (N=59; 62; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426.59" spread="418.38"/>
                    <measurement group_id="O2" value="228.06" spread="215.33"/>
                    <measurement group_id="O3" value="451.90" spread="400.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4- IFN-γ] D 0 (N=61; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.59" spread="532.27"/>
                    <measurement group_id="O2" value="319.38" spread="507.10"/>
                    <measurement group_id="O3" value="824.76" spread="496.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4- IFN-γ] D 21 (N=62; 60; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1219.72" spread="1581.26"/>
                    <measurement group_id="O2" value="721.43" spread="849.49"/>
                    <measurement group_id="O3" value="1361.31" spread="712.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4- IFN-γ] D 42 (N=58; 62; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="903.71" spread="918.49"/>
                    <measurement group_id="O2" value="517.83" spread="501.51"/>
                    <measurement group_id="O3" value="1095.12" spread="676.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4- IFN-γ] D 180 (N=57; 60; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="697.03" spread="635.80"/>
                    <measurement group_id="O2" value="510.37" spread="539.79"/>
                    <measurement group_id="O3" value="1253.33" spread="862.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-IL2] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346.00" spread="369.76"/>
                    <measurement group_id="O2" value="319.16" spread="331.16"/>
                    <measurement group_id="O3" value="677.11" spread="397.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-IL2] D 21 (N=62; 61; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872.32" spread="897.70"/>
                    <measurement group_id="O2" value="427.26" spread="664.07"/>
                    <measurement group_id="O3" value="816.95" spread="655.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-IL2] D 42 (N=60; 64; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696.36" spread="598.29"/>
                    <measurement group_id="O2" value="393.67" spread="460.81"/>
                    <measurement group_id="O3" value="720.28" spread="468.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-IL2] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570.30" spread="503.83"/>
                    <measurement group_id="O2" value="387.63" spread="429.61"/>
                    <measurement group_id="O3" value="817.80" spread="470.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-IL2] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.66" spread="306.46"/>
                    <measurement group_id="O2" value="240.26" spread="261.18"/>
                    <measurement group_id="O3" value="369.77" spread="322.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-IL2] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.16" spread="1060.47"/>
                    <measurement group_id="O2" value="391.84" spread="425.96"/>
                    <measurement group_id="O3" value="510.88" spread="385.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-IL2] D 42 (N=59; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534.07" spread="579.96"/>
                    <measurement group_id="O2" value="295.90" spread="322.75"/>
                    <measurement group_id="O3" value="438.09" spread="401.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-IL2] D 180 (N=59; 62; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526.12" spread="483.57"/>
                    <measurement group_id="O2" value="299.67" spread="274.20"/>
                    <measurement group_id="O3" value="514.55" spread="404.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-IL2] D 0 (N=61; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587.16" spread="566.46"/>
                    <measurement group_id="O2" value="451.89" spread="549.60"/>
                    <measurement group_id="O3" value="1019.08" spread="512.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-IL2] D 21 (N=62; 60; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1496.41" spread="1826.01"/>
                    <measurement group_id="O2" value="1004.17" spread="966.20"/>
                    <measurement group_id="O3" value="1592.61" spread="810.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-IL2] D 42 (N=58; 62; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1144.72" spread="1021.68"/>
                    <measurement group_id="O2" value="724.10" spread="593.13"/>
                    <measurement group_id="O3" value="1322.64" spread="664.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-IL2] D 180 (N=57; 60; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="933.06" spread="660.87"/>
                    <measurement group_id="O2" value="704.18" spread="602.50"/>
                    <measurement group_id="O3" value="1439.92" spread="753.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-TNF-α] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.44" spread="349.53"/>
                    <measurement group_id="O2" value="247.22" spread="274.83"/>
                    <measurement group_id="O3" value="536.34" spread="369.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-TNF-α] D 21 (N=62; 61; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621.35" spread="746.04"/>
                    <measurement group_id="O2" value="289.38" spread="376.07"/>
                    <measurement group_id="O3" value="497.77" spread="499.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-TNF-α] D 42 (N=60; 64; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500.13" spread="518.12"/>
                    <measurement group_id="O2" value="238.28" spread="329.62"/>
                    <measurement group_id="O3" value="564.91" spread="395.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain[CD4-TNF-α] D 180 (N=60; 63; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462.60" spread="402.23"/>
                    <measurement group_id="O2" value="308.96" spread="347.12"/>
                    <measurement group_id="O3" value="616.75" spread="383.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-TNF-α] D 0 (N=62; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.83" spread="292.61"/>
                    <measurement group_id="O2" value="191.52" spread="234.42"/>
                    <measurement group_id="O3" value="284.69" spread="317.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-TNF-α] D 21 (N=62; 61; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600.99" spread="932.13"/>
                    <measurement group_id="O2" value="320.59" spread="308.63"/>
                    <measurement group_id="O3" value="411.24" spread="333.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-TNF-α] D 42 (N=59; 64; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.35" spread="515.50"/>
                    <measurement group_id="O2" value="211.12" spread="267.39"/>
                    <measurement group_id="O3" value="333.52" spread="375.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain[CD4-TNF-α] D 180 (N=59; 62; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370.86" spread="415.54"/>
                    <measurement group_id="O2" value="230.70" spread="241.03"/>
                    <measurement group_id="O3" value="477.18" spread="355.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-TNF-α] D 0 (N=61; 61; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.10" spread="472.20"/>
                    <measurement group_id="O2" value="305.51" spread="516.15"/>
                    <measurement group_id="O3" value="773.44" spread="420.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-TNF-α] D 21 (N=62; 60; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967.79" spread="1226.62"/>
                    <measurement group_id="O2" value="639.74" spread="663.66"/>
                    <measurement group_id="O3" value="1057.83" spread="507.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-TNF-α] D 42 (N=58; 62; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="775.92" spread="756.63"/>
                    <measurement group_id="O2" value="413.38" spread="490.41"/>
                    <measurement group_id="O3" value="953.30" spread="491.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain[CD4-TNF-α] D 180 (N=57; 60; 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="642.05" spread="520.83"/>
                    <measurement group_id="O2" value="475.44" spread="511.57"/>
                    <measurement group_id="O3" value="1051.51" spread="664.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemagglutinin Inhibition (HI) Antibody Titers</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs) calculated after invitro stimulation with separate vaccine strains.</description>
        <time_frame>At Day 0, 21, 42 and 180</time_frame>
        <population>The analysis of immunogenicity was performed on According-to-Protocol (ATP) Immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutinin Inhibition (HI) Antibody Titers</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs) calculated after invitro stimulation with separate vaccine strains.</description>
          <population>The analysis of immunogenicity was performed on According-to-Protocol (ATP) Immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.7" upper_limit="21.5"/>
                    <measurement group_id="O2" value="14.3" lower_limit="10.9" upper_limit="18.7"/>
                    <measurement group_id="O3" value="20.5" lower_limit="13.0" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.1" lower_limit="80.3" upper_limit="137.6"/>
                    <measurement group_id="O2" value="67.2" lower_limit="49.6" upper_limit="91.2"/>
                    <measurement group_id="O3" value="220.8" lower_limit="163.3" upper_limit="298.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="64.5" upper_limit="105.0"/>
                    <measurement group_id="O2" value="56.8" lower_limit="42.0" upper_limit="77.0"/>
                    <measurement group_id="O3" value="181.4" lower_limit="133.5" upper_limit="246.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" lower_limit="30.3" upper_limit="48.7"/>
                    <measurement group_id="O2" value="32.1" lower_limit="24.0" upper_limit="42.8"/>
                    <measurement group_id="O3" value="90.3" lower_limit="60.7" upper_limit="134.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="15.0" upper_limit="30.4"/>
                    <measurement group_id="O2" value="17.5" lower_limit="13.2" upper_limit="23.3"/>
                    <measurement group_id="O3" value="16.4" lower_limit="11.0" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.9" lower_limit="239.8" upper_limit="456.7"/>
                    <measurement group_id="O2" value="164.2" lower_limit="113.3" upper_limit="238.0"/>
                    <measurement group_id="O3" value="179.0" lower_limit="115.1" upper_limit="278.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.8" lower_limit="182.1" upper_limit="356.5"/>
                    <measurement group_id="O2" value="110.1" lower_limit="77.4" upper_limit="156.6"/>
                    <measurement group_id="O3" value="130.3" lower_limit="86.6" upper_limit="196.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.0" lower_limit="83.0" upper_limit="164.9"/>
                    <measurement group_id="O2" value="59.9" lower_limit="41.8" upper_limit="85.9"/>
                    <measurement group_id="O3" value="74.4" lower_limit="47.6" upper_limit="116.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="66.2" upper_limit="127.8"/>
                    <measurement group_id="O2" value="97.0" lower_limit="72.9" upper_limit="129.2"/>
                    <measurement group_id="O3" value="169.0" lower_limit="108.2" upper_limit="263.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="699.9" lower_limit="538.4" upper_limit="909.8"/>
                    <measurement group_id="O2" value="502.6" lower_limit="388.6" upper_limit="650.0"/>
                    <measurement group_id="O3" value="1229.4" lower_limit="972.8" upper_limit="1553.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.2" lower_limit="372.2" upper_limit="637.8"/>
                    <measurement group_id="O2" value="393.9" lower_limit="310.3" upper_limit="500"/>
                    <measurement group_id="O3" value="971.6" lower_limit="778.0" upper_limit="1213.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.5" lower_limit="195.3" upper_limit="331.6"/>
                    <measurement group_id="O2" value="238.4" lower_limit="188.4" upper_limit="301.6"/>
                    <measurement group_id="O3" value="677.2" lower_limit="513.7" upper_limit="892.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains.</title>
        <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10</description>
        <time_frame>At Day 0, 21, 42 and 180</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains.</title>
          <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies</title>
        <description>Seroconversion was defined as the number of vaccinees who had either a prevaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>At Day 21, 42 and 180</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies</title>
          <description>Seroconversion was defined as the number of vaccinees who had either a prevaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors</title>
        <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
        <time_frame>At Day 21, 42 and 180</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Seroconversion Factors</title>
          <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="4.5" upper_limit="9.0"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.4" upper_limit="6.6"/>
                    <measurement group_id="O3" value="10.6" lower_limit="6.3" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.7" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.8" upper_limit="5.4"/>
                    <measurement group_id="O3" value="8.9" lower_limit="5.3" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.7" upper_limit="3.0"/>
                    <measurement group_id="O3" value="4.6" lower_limit="2.9" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="10.8" upper_limit="22.2"/>
                    <measurement group_id="O2" value="9.4" lower_limit="6.6" upper_limit="13.2"/>
                    <measurement group_id="O3" value="11.3" lower_limit="7.2" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="8.5" upper_limit="17.4"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.7" upper_limit="8.6"/>
                    <measurement group_id="O3" value="7.9" lower_limit="5.3" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.1" upper_limit="7.3"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.5" upper_limit="4.6"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.6" upper_limit="10.3"/>
                    <measurement group_id="O2" value="5.2" lower_limit="3.8" upper_limit="7.1"/>
                    <measurement group_id="O3" value="7.4" lower_limit="4.7" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.1" upper_limit="5.4"/>
                    <measurement group_id="O3" value="5.8" lower_limit="3.7" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.2" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.9" upper_limit="3.1"/>
                    <measurement group_id="O3" value="4.0" lower_limit="2.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Day 0, 21, 42 and 180</time_frame>
        <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
          <population>The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 0 (N=62; 66; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 21 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 42 (N=61; 65; 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane strain at Day 180 (N=62; 66; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 ecchymosis, redness and swelling was &gt;100mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activity.</description>
        <time_frame>Day 0 -6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Grade 3 ecchymosis, redness and swelling was &gt;100mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activity.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local AEs</title>
        <description>Duration was defined as the number of days with any grade of local symptoms.</description>
        <time_frame>Day 0 -6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs</title>
          <description>Duration was defined as the number of days with any grade of local symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N=2; 1; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=43; 15; 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=5; 0; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=8; 1; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was defined as oral temperature ≥ 39.0°C. For other symptoms grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0 -6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
          <description>Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was defined as oral temperature ≥ 39.0°C. For other symptoms grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited General AEs</title>
        <description>Duration was defined as number of days with any grade of general symptoms.</description>
        <time_frame>Day 0 -6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General AEs</title>
          <description>Duration was defined as number of days with any grade of general symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=14; 3; 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=22; 12; 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms (N=6; 4; 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=22; 7; 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=17; 8; 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=11; 0; 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="2.5" lower_limit="2.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=2; 0; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom, regardless of intensity or relation to vaccination, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom, regardless of intensity or relation to vaccination, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs)</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination, grade 3 was defined as symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-179</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs)</title>
          <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination, grade 3 was defined as symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any AEs of Specific Interest (AESI)</title>
        <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination.</description>
        <time_frame>Day 0-364</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any AEs of Specific Interest (AESI)</title>
          <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination and related was event assessed by investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-364</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination and related was event assessed by investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed up to day 364. Systematically assessed frequent adverse events (AEs) were assessed during 7 day post vaccination period. Non systematically assessed frequent AEs were assessed during 21 day post vaccination period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged &gt;= 65 years receiving 1 dose of Fluarix vaccine at Day 0</description>
        </group>
        <group group_id="E3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

